+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Epinephrine Auto-injector - Global Market Trajectory & Analytics

  • ID: 5028116
  • Report
  • April 2021
  • Region: Global
  • 176 pages
  • Global Industry Analysts, Inc
Global Epinephrine Auto-injector Market to Reach $2.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Epinephrine Auto-injector estimated at US$1.8 Billion in the year 2020, is projected to reach a revised size of US$2.7 Billion by 2027, growing at a CAGR of 5.6% over the analysis period 2020-2027. 0.15gm Dosage, one of the segments analyzed in the report, is projected to record a 6% CAGR and reach US$1.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the 0.30gm Dosage segment is readjusted to a revised 5.1% CAGR for the next 7-year period.



The U.S. Market is Estimated at $535 Million, While China is Forecast to Grow at 5.2% CAGR

The Epinephrine Auto-injector market in the U.S. is estimated at US$535 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$467.1 Million by the year 2027 trailing a CAGR of 5.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 4.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

0.5gm Dosage Segment to Record 3.5% CAGR

In the global 0.5gm Dosage segment, USA, Canada, Japan, China and Europe will drive the 3.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$108.9 Million in the year 2020 will reach a projected size of US$138.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$304.9 Million by the year 2027.

Select Competitors (Total 44 Featured):
  • Adamis Pharmaceuticals Corporation
  • ALK-Abello AS
  • Antares Pharma, Inc.
  • Bausch + Lomb UK Ltd- Emerade
  • Hospira, Inc.
  • Impax Laboratories, Inc.
  • Lincoln Medical
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for Epinephrine Auto-injector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Epinephrine Auto-injector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Epinephrine Auto-injector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for 0.15gm Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for 0.15gm Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for 0.15gm Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for 0.30gm Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for 0.30gm Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for 0.30gm Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for 0.5gm Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for 0.5gm Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for 0.5gm Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 16: World Current & Future Analysis for Individuals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 17: World Historic Review for Individuals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 18: World 15-Year Perspective for Individuals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • Table 19: USA Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 20: USA Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 21: USA 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
  • Table 22: USA Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 23: USA Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 24: USA 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • Table 25: Canada Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 26: Canada Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 27: Canada 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
  • Table 28: Canada Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 29: Canada Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 30: Canada 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • Table 31: Japan Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 32: Japan Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 33: Japan 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
  • Table 34: Japan Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 35: Japan Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 36: Japan 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • Table 37: China Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 38: China Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 39: China 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
  • Table 40: China Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 41: China Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 42: China 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • Table 43: Europe Current & Future Analysis for Epinephrine Auto-injector by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 44: Europe Historic Review for Epinephrine Auto-injector by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 45: Europe 15-Year Perspective for Epinephrine Auto-injector by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 46: Europe Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 47: Europe Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 48: Europe 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
  • Table 49: Europe Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 50: Europe Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 51: Europe 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • Table 52: France Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 53: France Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 54: France 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
  • Table 55: France Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 56: France Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 57: France 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • Table 58: Germany Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 59: Germany Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 60: Germany 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
  • Table 61: Germany Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 62: Germany Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 63: Germany 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • Table 64: Italy Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 65: Italy Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 66: Italy 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
  • Table 67: Italy Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 68: Italy Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 69: Italy 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • Table 70: UK Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 71: UK Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 72: UK 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
  • Table 73: UK Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 74: UK Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 75: UK 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • Table 76: Rest of Europe Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 77: Rest of Europe Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 78: Rest of Europe 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
  • Table 79: Rest of Europe Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 80: Rest of Europe Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 81: Rest of Europe 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • Table 82: Asia-Pacific Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 83: Asia-Pacific Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 84: Asia-Pacific 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
  • Table 85: Asia-Pacific Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 86: Asia-Pacific Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 87: Asia-Pacific 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
  • Table 88: Rest of World Current & Future Analysis for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 89: Rest of World Historic Review for Epinephrine Auto-injector by Dosage - 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 90: Rest of World 15-Year Perspective for Epinephrine Auto-injector by Dosage - Percentage Breakdown of Value Sales for 0.15gm Dosage, 0.30gm Dosage and 0.5gm Dosage for the Years 2012, 2020 & 2027
  • Table 91: Rest of World Current & Future Analysis for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 92: Rest of World Historic Review for Epinephrine Auto-injector by End-Use - Hospitals & Clinics and Individuals Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 93: Rest of World 15-Year Perspective for Epinephrine Auto-injector by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Individuals for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 44
Note: Product cover images may vary from those shown
Adroll
adroll